Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97840 | 0.77 | ADRB2 (0.51) | ADRB2ADRB1HTR1AOPRK1NPC1 | |
| SCHEMBL30636067 | 0.77 | ADRB2 (0.51) | ADRB2ADRB1HTR1AOPRK1NPC1 | |
| SCHEMBL4893063 | 0.77 | SMYD3 (0.38) | ADRB2ADRB1HTR1AOPRK1 | |
| SCHEMBL7737243 | 0.76 | PARP1 (0.35) | ADRB2ADRB1HTR1AOPRK1 | |
| SCHEMBL29993176 | 0.75 | ADRB2 (0.43) | ADRB2ADRB1HTR1A | |
| SCHEMBL1660912 | 0.75 | ADRB2 (0.43) | ADRB2ADRB1HTR1A | |
| SCHEMBL1764193 | 0.74 | ADRB2 (0.57) | ADRB2ADRB1HTR1AOPRK1NPC1 | |
| SCHEMBL10569911 | 0.72 | ADRB2 (0.50) | ADRB2ADRB1HTR1AOPRK1NPC1 | |
| SCHEMBL11169736 | 0.72 | ADRB1 (0.47) | ADRB2ADRB1HTR1AOPRK1NPC1 | |
| SCHEMBL10577760 | 0.72 | ADRB1 (0.46) | ADRB2ADRB1HTR1AOPRK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | ADRB2 252/4885ADRB1 146/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.